通过多组学分析解析类风湿关节炎中抗白介素-6受体与抗肿瘤坏死因子-α治疗应答的差异生物标志物
本研究利用MONARCH试验(NCT02332590)的血样,在基线、第2周和第24周通过Olink蛋白质组学(n=804份血清样本,来自268例患者)和RNA测序(n=522份外周血样本,来自261例患者)分析抗IL-6R与抗TNF-α治疗类风湿关节炎的预测性和药效学生物标志物。结果显示两种治疗最具预测性的血清标志物不同,抗IL-6R标志物与先天免疫激活和滑膜炎症相关,抗TNF-α标志物似乎更与T细胞和中性粒细胞相关,且两者药效学效应和通路特征不同。
要点
- 抗IL-6R与抗TNF-α最具预测性的血清标志物不同,分别与先天免疫/滑膜炎症和T细胞/中性粒细胞相关。
- 两种治疗在基线预测标志物及第2周和第24周药效学生物标志物与通路特征上效应不同。
- 单标志物及组合标志物的绝对预测性能在交叉验证中有限,需关注相对预测。
核心结论
- 无偏血清蛋白分析识别出在不同时间点最能预测抗IL-6R和抗TNF-α治疗的生物标志物,可解释类风湿关节炎患者应答率的差异。
- 生物标志物和通路结果均凸显两种治疗的作用模式存在差异。
研究设计与样本
- 本研究使用MONARCH试验(NCT02332590)的血样,该试验为随机、双盲、III期试验,比较沙利鲁单抗(抗IL-6R)与阿达木单抗(抗TNF-α)单药治疗对甲氨蝶呤不耐受/应答不佳的类风湿关节炎患者的安全性和有效性。
- 采用Olink蛋白质组学分析基线、第2周和第24周的预测性和药效学生物标志物,纳入268例患者的804份血清样本。
- 采用RNA测序分析两种治疗对基因表达水平的变化,纳入261例患者的522份外周血样本。
主要发现
- 抗IL-6R最具预测性的血清标志物与抗TNF-α不同;抗IL-6R预测标志物与先天免疫激活和滑膜炎症相关,抗TNF-α预测标志物似乎更与T细胞和中性粒细胞相关。
- 单标志物及组合标志物使用交叉验证的绝对预测性能有限,因此基线预测标志物需关注相对预测。
- 抗IL-6R与抗TNF-α对生物标志物及通路特征的药效学效应不同。
临床怎么用
- 原文未据此给出推荐。
局限性
- 单标志物及组合标志物使用交叉验证的绝对预测性能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify blood-based predictive and pharmacodynamic biomarkers at different timepoints in patients with active rheumatoid arthritis (RA) treated with anti-interleukin-6 receptor (anti-IL-6R) and anti-tumour necrosis factor-α (anti-TNF-α). METHODS: This study used blood samples from the MONARCH trial (NCT02332590), a randomised, double-blind, phase III trial that compared the safety and efficacy of sarilumab (anti-IL-6R) and adalimumab (anti-TNF-α) monotherapy in patients with RA who were intolerant/inadequate responders to methotrexate. The study evaluated predictive biomarkers to anti-IL-6R and anti-TNF-α treatments at baseline and week 2 and pharmacodynamic biomarkers at week 2 and week 24 using Olink proteomics analysis (n=804 serum samples from 268 patients). Change in gene expression levels (n=522 peripheral blood samples from 261 patients) by both treatments was assessed using RNA sequencing analysis. RESULTS: Serum biomarkers most predictive to anti-IL-6R were different from those of anti-TNF-α; predictive biomarkers for anti-IL-6R were correlated with innate immune activation and synovial inflammation, while predictive biomarkers for anti-TNF-α seemed to be more T-cell and neutrophil-related. For baseline predictive biomarkers, we had to focus on relative prediction as the absolute prediction performance of single and combination biomarkers using cross-validation was limited. Additionally, the pharmacodynamic effects of anti-IL-6R and anti-TNF-α on biomarkers as well as pathway signatures were distinct. CONCLUSION: The unbiased analysis of serum proteins identified biomarkers most predictive of anti-IL-6R and anti-TNF-α at different timepoints that could explain the difference in the response rate in patients with RA. Further, both biomarker and pathway results highlighted a differentiated mode of action of both treatments.
引用
- Agueusop I, Margerie D, Remaury A, et al. Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis. RMD Open. 2025. PMID: 40759562. doi:10.1136/rmdopen-2025-005556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。